Comparison of four antiemetic regimens for the treatment of cisplatin-induced vomiting

R. Póka, Z. Hernádi, B. Juhász, L. Lampé

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

OBJECTIVE: To improve the treatment of cisplatin-induced acute emesis and vomiting, the adjuvant effect of two different doses of metoclopramide and metoclopramide plus droperidol was compared to a defined standard antiemetic regiment. METHOD: One-hundred and twenty-one consecutive cisplatin-based chemotherapy treatments for ovarian carcinoma were randomly assigned to receive standard plus no adjuvant (control, n = 24), high-dose metoclopramide (HDM, n = 33), very high dose metoclopramide (VHDM, n = 50) and very high dose metoclopramide plus droperidol (VHDM + DP, n = 14) antiemetic treatment. The number of vomiting episodes up to 4 h after the treatment were recorded and compared in the four different antiemetic groups. The effect of the number of previous chemotherapy cycles, the strength of previous antiemetic treatments, age and stage of disease on the number of vomiting episodes was also assessed. RESULT: The mean number of vomiting episodes during the first 4 h after the chemotherapy was 9, 6.4, 6.2 and 2.7 among patients receiving the standard HDM, VHDM and VHDM + DP antiemetic regimens, respectively. Analysis of variance of vomiting episodes confirmed significant differences between the groups (P <0.001, F = 406.5, df = 120). The number of previous chemotherapy cycles and, to a lesser extent, the stage of disease, the strength of previous antiemetic regimens and the age showed significant correlation with the number of vomiting episodes (r = 0.443, -0.159, -0.14 and -0.009 respectively). CONCLUSION: Substantial improvement in the control of cisplating-induced vomiting can be achieved by adding high-dose metoclopramide and droperidol to a basic antiemetic regimen consisting prochlorperazine, dexamethasone and thiethylperazine.

Original languageEnglish
Pages (from-to)19-24
Number of pages6
JournalInternational Journal of Gynecology and Obstetrics
Volume42
Issue number1
DOIs
Publication statusPublished - 1993

Fingerprint

Antiemetics
Cisplatin
Metoclopramide
Vomiting
Droperidol
Drug Therapy
Therapeutics
Thiethylperazine
Prochlorperazine
Dexamethasone
Analysis of Variance
Carcinoma

Keywords

  • Cisplatin
  • Droperidol
  • Metoclopramide
  • Ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Comparison of four antiemetic regimens for the treatment of cisplatin-induced vomiting. / Póka, R.; Hernádi, Z.; Juhász, B.; Lampé, L.

In: International Journal of Gynecology and Obstetrics, Vol. 42, No. 1, 1993, p. 19-24.

Research output: Contribution to journalArticle

@article{0b77cf9e57c44500a461c8cd1a2386f0,
title = "Comparison of four antiemetic regimens for the treatment of cisplatin-induced vomiting",
abstract = "OBJECTIVE: To improve the treatment of cisplatin-induced acute emesis and vomiting, the adjuvant effect of two different doses of metoclopramide and metoclopramide plus droperidol was compared to a defined standard antiemetic regiment. METHOD: One-hundred and twenty-one consecutive cisplatin-based chemotherapy treatments for ovarian carcinoma were randomly assigned to receive standard plus no adjuvant (control, n = 24), high-dose metoclopramide (HDM, n = 33), very high dose metoclopramide (VHDM, n = 50) and very high dose metoclopramide plus droperidol (VHDM + DP, n = 14) antiemetic treatment. The number of vomiting episodes up to 4 h after the treatment were recorded and compared in the four different antiemetic groups. The effect of the number of previous chemotherapy cycles, the strength of previous antiemetic treatments, age and stage of disease on the number of vomiting episodes was also assessed. RESULT: The mean number of vomiting episodes during the first 4 h after the chemotherapy was 9, 6.4, 6.2 and 2.7 among patients receiving the standard HDM, VHDM and VHDM + DP antiemetic regimens, respectively. Analysis of variance of vomiting episodes confirmed significant differences between the groups (P <0.001, F = 406.5, df = 120). The number of previous chemotherapy cycles and, to a lesser extent, the stage of disease, the strength of previous antiemetic regimens and the age showed significant correlation with the number of vomiting episodes (r = 0.443, -0.159, -0.14 and -0.009 respectively). CONCLUSION: Substantial improvement in the control of cisplating-induced vomiting can be achieved by adding high-dose metoclopramide and droperidol to a basic antiemetic regimen consisting prochlorperazine, dexamethasone and thiethylperazine.",
keywords = "Cisplatin, Droperidol, Metoclopramide, Ovarian cancer",
author = "R. P{\'o}ka and Z. Hern{\'a}di and B. Juh{\'a}sz and L. Lamp{\'e}",
year = "1993",
doi = "10.1016/0020-7292(93)90440-8",
language = "English",
volume = "42",
pages = "19--24",
journal = "International Journal of Gynecology and Obstetrics",
issn = "0020-7292",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Comparison of four antiemetic regimens for the treatment of cisplatin-induced vomiting

AU - Póka, R.

AU - Hernádi, Z.

AU - Juhász, B.

AU - Lampé, L.

PY - 1993

Y1 - 1993

N2 - OBJECTIVE: To improve the treatment of cisplatin-induced acute emesis and vomiting, the adjuvant effect of two different doses of metoclopramide and metoclopramide plus droperidol was compared to a defined standard antiemetic regiment. METHOD: One-hundred and twenty-one consecutive cisplatin-based chemotherapy treatments for ovarian carcinoma were randomly assigned to receive standard plus no adjuvant (control, n = 24), high-dose metoclopramide (HDM, n = 33), very high dose metoclopramide (VHDM, n = 50) and very high dose metoclopramide plus droperidol (VHDM + DP, n = 14) antiemetic treatment. The number of vomiting episodes up to 4 h after the treatment were recorded and compared in the four different antiemetic groups. The effect of the number of previous chemotherapy cycles, the strength of previous antiemetic treatments, age and stage of disease on the number of vomiting episodes was also assessed. RESULT: The mean number of vomiting episodes during the first 4 h after the chemotherapy was 9, 6.4, 6.2 and 2.7 among patients receiving the standard HDM, VHDM and VHDM + DP antiemetic regimens, respectively. Analysis of variance of vomiting episodes confirmed significant differences between the groups (P <0.001, F = 406.5, df = 120). The number of previous chemotherapy cycles and, to a lesser extent, the stage of disease, the strength of previous antiemetic regimens and the age showed significant correlation with the number of vomiting episodes (r = 0.443, -0.159, -0.14 and -0.009 respectively). CONCLUSION: Substantial improvement in the control of cisplating-induced vomiting can be achieved by adding high-dose metoclopramide and droperidol to a basic antiemetic regimen consisting prochlorperazine, dexamethasone and thiethylperazine.

AB - OBJECTIVE: To improve the treatment of cisplatin-induced acute emesis and vomiting, the adjuvant effect of two different doses of metoclopramide and metoclopramide plus droperidol was compared to a defined standard antiemetic regiment. METHOD: One-hundred and twenty-one consecutive cisplatin-based chemotherapy treatments for ovarian carcinoma were randomly assigned to receive standard plus no adjuvant (control, n = 24), high-dose metoclopramide (HDM, n = 33), very high dose metoclopramide (VHDM, n = 50) and very high dose metoclopramide plus droperidol (VHDM + DP, n = 14) antiemetic treatment. The number of vomiting episodes up to 4 h after the treatment were recorded and compared in the four different antiemetic groups. The effect of the number of previous chemotherapy cycles, the strength of previous antiemetic treatments, age and stage of disease on the number of vomiting episodes was also assessed. RESULT: The mean number of vomiting episodes during the first 4 h after the chemotherapy was 9, 6.4, 6.2 and 2.7 among patients receiving the standard HDM, VHDM and VHDM + DP antiemetic regimens, respectively. Analysis of variance of vomiting episodes confirmed significant differences between the groups (P <0.001, F = 406.5, df = 120). The number of previous chemotherapy cycles and, to a lesser extent, the stage of disease, the strength of previous antiemetic regimens and the age showed significant correlation with the number of vomiting episodes (r = 0.443, -0.159, -0.14 and -0.009 respectively). CONCLUSION: Substantial improvement in the control of cisplating-induced vomiting can be achieved by adding high-dose metoclopramide and droperidol to a basic antiemetic regimen consisting prochlorperazine, dexamethasone and thiethylperazine.

KW - Cisplatin

KW - Droperidol

KW - Metoclopramide

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0027257868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027257868&partnerID=8YFLogxK

U2 - 10.1016/0020-7292(93)90440-8

DO - 10.1016/0020-7292(93)90440-8

M3 - Article

VL - 42

SP - 19

EP - 24

JO - International Journal of Gynecology and Obstetrics

JF - International Journal of Gynecology and Obstetrics

SN - 0020-7292

IS - 1

ER -